Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
1/5 보강
Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory.
APA
Cabanillas ME, Busaidy NL, Sherman SI (2022). Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(19), 4164-4166. https://doi.org/10.1158/1078-0432.CCR-22-1710
MLA
Cabanillas ME, et al.. "Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.." Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 19, 2022, pp. 4164-4166.
PMID
35895318 ↗
Abstract 한글 요약
Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the holy grail in endocrine oncology. See related article by Weber et al., p. 4194.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.